Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CRDF logo

Cardiff Oncology Inc (CRDF)CRDF

Upturn stock ratingUpturn stock rating
Cardiff Oncology Inc
$2.66
Delayed price
PASS
upturn advisory
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

12/02/2024: CRDF (2-star) is currently NOT-A-BUY. Pass it for now.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: PASS
Historic Profit: 37.27%
Upturn Advisory Performance Upturn Advisory Performance2
Avg. Invested days: 41
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 3
Last Close 12/02/2024
Type: Stock
Today’s Advisory: PASS
Historic Profit: 37.27%
Avg. Invested days: 41
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 3
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 12/02/2024
Upturn Advisory Performance Upturn Advisory Performance2

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 133.46M USD
Price to earnings Ratio -
1Y Target Price 9.16
Dividends yield (FY) -
Basic EPS (TTM) -0.95
Volume (30-day avg) 928818
Beta 1.93
52 Weeks Range 1.21 - 6.42
Updated Date 12/2/2024
Company Size Small-Cap Stock
Market Capitalization 133.46M USD
Price to earnings Ratio -
1Y Target Price 9.16
Dividends yield (FY) -
Basic EPS (TTM) -0.95
Volume (30-day avg) 928818
Beta 1.93
52 Weeks Range 1.21 - 6.42
Updated Date 12/2/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -7636.97%

Management Effectiveness

Return on Assets (TTM) -38.33%
Return on Equity (TTM) -67.57%

Revenue by Products

Revenue by Products - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 77478079
Price to Sales(TTM) 193.98
Enterprise Value to Revenue 112.61
Enterprise Value to EBITDA -3.66
Shares Outstanding 51133700
Shares Floating 47757386
Percent Insiders 6.6
Percent Institutions 25.98
Trailing PE -
Forward PE -
Enterprise Value 77478079
Price to Sales(TTM) 193.98
Enterprise Value to Revenue 112.61
Enterprise Value to EBITDA -3.66
Shares Outstanding 51133700
Shares Floating 47757386
Percent Insiders 6.6
Percent Institutions 25.98

Analyst Ratings

Rating 4.6
Target Price 7.33
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -
Rating 4.6
Target Price 7.33
Buy 2
Strong Buy 3
Hold -
Sell -
Strong Sell -

AI Summarization

Cardiff Oncology Inc. (CRDF): A Comprehensive Overview

Company Profile:

History and Background:

Cardiff Oncology Inc. (CRDF) is a clinical-stage biopharmaceutical company founded in 2014. It focuses on developing innovative therapies for patients with unmet medical needs in hematological malignancies and solid tumors. The company leverages its expertise in tumor biology and precision medicine to identify and advance promising drug candidates through clinical development.

Core Business Areas:

Cardiff Oncology's primary focus lies in the discovery, development, and commercialization of novel antibody-drug conjugates (ADCs) and other targeted therapies. Its pipeline includes several candidates in various stages of clinical development, with two lead programs:

  • CRD-3454: An ADC targeting CD74 for the treatment of hematological malignancies.
  • CRD-5521: An ADC targeting HER3 for the treatment of solid tumors.

Leadership and Corporate Structure:

The company's leadership team comprises experienced professionals from the pharmaceutical and biotechnology industry. Dr. Jeffrey L. Hoeg, a seasoned leader with extensive expertise in drug development, serves as President and CEO. The executive team also includes individuals with expertise in finance, research and development, clinical operations, and regulatory affairs.

Top Products and Market Share:

Currently, Cardiff Oncology does not have any marketed products. All its products are in the clinical development stage. Therefore, market share analysis is not applicable at this point.

Total Addressable Market:

According to a report by GlobalData, the global market for cancer drugs is estimated to reach US$308.8 billion by 2025. The market for ADCs is projected to experience significant growth, driven by increased adoption and promising clinical data. This presents a substantial addressable market for Cardiff Oncology as it advances its ADC programs.

Financial Performance:

Cardiff Oncology is a pre-revenue company with ongoing clinical trials. As of its latest financial reporting, the company had no product revenue and incurred significant research and development expenses. The company's financial performance is primarily evaluated based on cash used in operating activities, net loss, and ability to secure funding to continue its operations.

Dividends and Shareholder Returns:

As a pre-revenue company, Cardiff Oncology does not currently pay dividends to shareholders. The company's share price performance is primarily driven by its R&D progress, clinical trial results, and overall market sentiment towards the oncology sector.

Growth Trajectory:

Historical growth analysis is not applicable for Cardiff Oncology due to its lack of market presence and revenue generation. Future growth projections rely heavily on successful clinical trial outcomes, regulatory approvals, and potential product commercialization, making them difficult to predict with certainty.

Market Dynamics:

The oncology market is highly dynamic and competitive. Key trends include the development of personalized therapies, increased focus on immunotherapy, and growing demand for more effective and less toxic treatment options. Cardiff Oncology strives to capitalize on these trends by targeting its therapies towards specific unmet needs and leveraging innovative technologies.

Competitors:

Key competitors in the ADC space include Seattle Genetics (SGEN), ImmunoGen (IMGN), and Daiichi Sankyo (OTCPK:DSKYF). These companies have marketed ADCs and are also developing other pipeline candidates. Cardiff Oncology differentiates itself by focusing on novel targets and utilizing its proprietary linker technology for improved efficacy and safety profile.

Potential Challenges and Opportunities:

Challenges:

  • Uncertainties associated with clinical trial success
  • Competition from established players
  • Regulatory hurdles
  • Difficulty in raising capital

Opportunities:

  • Large unmet medical needs in the oncology space
  • Growing market for ADC therapies
  • Potential for strategic partnerships
  • Potential for product licensing deals

Recent Acquisitions (last 3 years):

Cardiff Oncology hasn't engaged in any notable acquisitions within the last three years.

AI-Based Fundamental Rating:

Overall Rating: 7/10

Justification:

Cardiff Oncology possesses a promising pipeline of novel drug candidates addressing significant unmet needs in cancer treatment. The company demonstrates a robust leadership team and technological expertise to compete in the dynamic oncology market. However, the pre-revenue stage and uncertainties related to clinical development necessitate a cautious outlook.

Sources and Disclaimers:

Sources used for this analysis include Cardiff Oncology's official website, company filings with the SEC, reports from reputable financial databases and industry research firms.

Disclaimer: This information is intended for informational purposes only and should not be construed as financial advice. Investors should conduct their own due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Cardiff Oncology Inc

Exchange NASDAQ Headquaters San Diego, CA, United States
IPO Launch date 2004-07-27 CEO & Director Dr. Mark Erlander Ph.D.
Sector Healthcare Website https://www.cardiffoncology.com
Industry Biotechnology Full time employees 31
Headquaters San Diego, CA, United States
CEO & Director Dr. Mark Erlander Ph.D.
Website https://www.cardiffoncology.com
Website https://www.cardiffoncology.com
Full time employees 31

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​